128 related articles for article (PubMed ID: 37664925)
1. MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer.
Lei Z; Wang P; Jia DQ; Li LL; Wu YP; Yang Y; Pan GQ
Front Biosci (Landmark Ed); 2023 Aug; 28(8):128. PubMed ID: 37664925
[TBL] [Abstract][Full Text] [Related]
2. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
[TBL] [Abstract][Full Text] [Related]
3. MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma.
Gu Y; Hu X; Liu X; Cheng C; Chen K; Wu Y; Wu Z
BMC Cancer; 2021 Jul; 21(1):784. PubMed ID: 34233647
[TBL] [Abstract][Full Text] [Related]
4. High MCM6 expression promotes proliferation and correlates with poor prognosis in triple-negative breast cancer.
Zhang H; Lin YD; Zhuang MX; Zhu L; Yu Y; Chen XG; Wang QS; Lin MB
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2906-2922. PubMed ID: 38639528
[TBL] [Abstract][Full Text] [Related]
5. Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma.
Hotton J; Agopiantz M; Leroux A; Charra-Brunaud C; Marie B; Busby-Venner H; Morel O; Guéant JL; Vignaud JM; Battaglia-Hsu SF; Gauchotte G
Virchows Arch; 2018 Apr; 472(4):623-633. PubMed ID: 29243125
[TBL] [Abstract][Full Text] [Related]
6. Minichromosome maintenance 6 complex component identified by bioinformatics analysis and experimental validation in esophageal squamous cell carcinoma.
Li X; Ren Z; Xiong C; Geng J; Li Y; Liu C; Ren C; Liu H
Oncol Rep; 2020 Sep; 44(3):987-1002. PubMed ID: 32583000
[TBL] [Abstract][Full Text] [Related]
7. High MCM6 Expression as a Potential Prognostic Marker in Clear-cell Renal Cell Carcinoma.
Jang NR; Baek J; Ko Y; Song PH; Gu MJ
In Vivo; 2021; 35(1):299-306. PubMed ID: 33402477
[TBL] [Abstract][Full Text] [Related]
8. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
[TBL] [Abstract][Full Text] [Related]
9. Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway.
Shao G; Fan X; Zhang P; Liu X; Huang L; Ji S
Aging (Albany NY); 2021 Feb; 13(4):4962-4975. PubMed ID: 33668040
[TBL] [Abstract][Full Text] [Related]
10. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression.
Liu Z; Li J; Chen J; Shan Q; Dai H; Xie H; Zhou L; Xu X; Zheng S
BMC Cancer; 2018 Feb; 18(1):200. PubMed ID: 29463213
[TBL] [Abstract][Full Text] [Related]
11. Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.
Pouget C; Hergalant S; Lardenois E; Lacomme S; Houlgatte R; Carpentier C; Dehais C; Rech F; Taillandier L; Sanson M; Appay R; Colin C; Figarella-Branger D; Battaglia-Hsu SF; Gauchotte G
Brain Pathol; 2020 May; 30(3):465-478. PubMed ID: 31561286
[TBL] [Abstract][Full Text] [Related]
12. The impact of MCM6 on hepatocellular carcinoma in a Southern Chinese Zhuang population.
Jia W; Xie L; Wang X; Zhang Q; Wei B; Li H; Qin S; Chen S; Liu J; Tan Y; Zheng S; Liang X; Yang X
Biomed Pharmacother; 2020 Jul; 127():110171. PubMed ID: 32403044
[TBL] [Abstract][Full Text] [Related]
13. Methyl(R217)HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinoma.
Vigouroux C; Casse JM; Battaglia-Hsu SF; Brochin L; Luc A; Paris C; Lacomme S; Gueant JL; Vignaud JM; Gauchotte G
Lung Cancer; 2015 Aug; 89(2):189-96. PubMed ID: 26013954
[TBL] [Abstract][Full Text] [Related]
14. The DNA replication regulator MCM6: An emerging cancer biomarker and target.
Zeng T; Guan Y; Li YK; Wu Q; Tang XJ; Zeng X; Ling H; Zou J
Clin Chim Acta; 2021 Jun; 517():92-98. PubMed ID: 33609557
[TBL] [Abstract][Full Text] [Related]
15. MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers.
Sadeghian D; Saffar H; Mahdavi Sharif P; Soleimani V; Jahanbin B
Diagn Pathol; 2022 Feb; 17(1):24. PubMed ID: 35125121
[TBL] [Abstract][Full Text] [Related]
16. TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
Jiang Y; Zhu C; Huang H; Huang G; Fu B; Xi X
BMC Cancer; 2023 Aug; 23(1):716. PubMed ID: 37528357
[TBL] [Abstract][Full Text] [Related]
17. Machine learning immune-related gene based on KLRB1 model for predicting the prognosis and immune cell infiltration of breast cancer.
Huang G; Xiao S; Jiang Z; Zhou X; Chen L; Long L; Zhang S; Xu K; Chen J; Jiang B
Front Endocrinol (Lausanne); 2023; 14():1185799. PubMed ID: 37351109
[TBL] [Abstract][Full Text] [Related]
18. GTSE1, CDC20, PCNA, and MCM6 Synergistically Affect Regulations in Cell Cycle and Indicate Poor Prognosis in Liver Cancer.
Zheng Y; Shi Y; Yu S; Han Y; Kang K; Xu H; Gu H; Sang X; Chen Y; Wang J
Anal Cell Pathol (Amst); 2019; 2019():1038069. PubMed ID: 32082966
[TBL] [Abstract][Full Text] [Related]
19.
Hou L; Zeng X; Li X; Zhao C; Zou J; Li Y; Liu G
Comput Math Methods Med; 2022; 2022():3116303. PubMed ID: 35720029
[TBL] [Abstract][Full Text] [Related]
20. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
Huang S; Dong C; Li D; Xu Y; Wu J
Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
[No Abstract] [Full Text] [Related]
[Next] [New Search]
